Intel Corporation Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

Earnings Per Share

Earnings Per Share

6 Months Ended

Jun. 28, 2025


Note 4 :			Earnings (Loss) Per Share

We computed basic earnings (loss) per share of common stock based on the weighted average number of shares of common stock outstanding during the period. We computed diluted earnings (loss) per share of common stock based on the weighted average number of shares of common stock outstanding plus potentially dilutive shares of common stock outstanding during the period, if applicable.


	Three Months Ended				Six Months Ended
(In Millions, Except Per Share Amounts)	Jun 28, 2025		Jun 29, 2024		Jun 28, 2025		Jun 29, 2024
Net income (loss)	$	(3,024)	$	(1,654)	$	(3,911)	$	(2,091)
Less: net income (loss) attributable to non-controlling interests	(106)		(44)		(172)		(100)
Net income (loss) attributable to Intel	$	(2,918)	$	(1,610)	$	(3,739)	$	(1,991)
Weighted average shares of common stock outstanding—basic	4,369		4,267		4,356		4,254


Weighted average shares of common stock outstanding—diluted	4,369		4,267		4,356		4,254
Earnings (loss) per share attributable to Intel—basic	$	(0.67)	$	(0.38)	$	(0.86)	$	(0.47)
Earnings (loss) per share attributable to Intel—diluted	$	(0.67)	$	(0.38)	$	(0.86)	$	(0.47)

Potentially dilutive shares of common stock from employee equity incentive plans are determined by applying the treasury stock method to the assumed exercise of outstanding stock options, the assumed vesting of outstanding RSUs, and the assumed issuance of common stock under the stock purchase plan. The potentially dilutive impact from the assumed issuance of common stock associated with a contractual conversion feature is determined by applying the if-converted method to the assumed exercise of the outstanding conversion feature.

Due to our net losses in the three and six months ended June 28, 2025 and June 29, 2024, the assumed exercise of outstanding stock options, the assumed vesting of outstanding RSUs, the assumed issuance of common stock under the stock purchase plan, and the assumed issuance of common stock associated with a contractual conversion feature, as applicable, had anti-dilutive effects on diluted loss per share and were excluded from the computations of diluted loss per share. In the three months ended June 28, 2025, securities that would have been anti-dilutive were insignificant and in the six months ended June 28, 2025, 158 million anti-dilutive shares were excluded from the computation of earnings (loss) per share. In the three and six months ended June 29, 2024, securities that would have been anti-dilutive were insignificant.